Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | November 21, 2007 | ||||
Last Updated Date | December 15, 2008 | ||||
Start Date † | May 2005 | ||||
Current Primary Outcome Measures † |
pathological response rate [ Time Frame: 12 months ] | ||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00563160 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
|
||||
Original Secondary Outcome Measures † | Same as current | ||||
Descriptive Information | |||||
Brief Title † | Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-Small-Cell Lung Cancer Before Surgery | ||||
Official Title † | Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-Small Cell Lung Cancer Before Surgery | ||||
Brief Summary | To study the activity of chemotherapy with Gemzar-carboplatin in the preoperative setting for operable stages of non-small-cell lung cancer and to identify novel molecular markers correlated with chemosensitivity and prognosis |
||||
Detailed Description | |||||
Study Phase | Phase II | ||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study | ||||
Condition † | Lung Neoplasms | ||||
Intervention † |
|
||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Recruiting | ||||
Enrollment † | 50 | ||||
Estimated Completion Date | February 2007 | ||||
Primary Completion Date | |||||
Eligibility Criteria † | Inclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years to 75 Years | ||||
Accepts Healthy Volunteers | |||||
Contacts †† |
|
||||
Location Countries † | China | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00563160 | ||||
Responsible Party | |||||
Secondary IDs †† | HARECCTR0500015, 000904, B9E-IH-O333 | ||||
Study Sponsor † | Hospital Authority, Hong Kong | ||||
Collaborators †† | Eli Lilly and Company | ||||
Investigators † |
|
||||
Information Provided By | Hospital Authority, Hong Kong | ||||
Verification Date | December 2008 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |